Advertisements

Quetiapine

Quick links to important sections

Quetiapine

Selected form

Advertisements
Advertisements

Treatment option: Bipolar Disorder, Schizophrenia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Quetiapine

Property Description
Active Ingredient Quetiapine fumarate
Form Tablets (Immediate-Release and Extended-Release)
Pharmacological Class Atypical Antipsychotic (Second-Generation Antipsychotic)
Common Use Management of psychosis and mood stabilization
Origin Synthetic compound

Defining Quetiapine: Type and Classification

Quetiapine is a synthetic compound classified pharmacologically as an atypical antipsychotic medication, belonging to the newer category of second-generation antipsychotics (SGA). The core medicinal substance is Quetiapine fumarate, chemically identified as a dibenzothiazepine derivative. Its classification as an SGA is based on its achievement of a clinical effect through a balance of binding to multiple brain receptors. This dual action is utilized for regulating the neurochemical imbalances that underlie disturbances in thought and emotional stability.

Form and General Therapeutic Purpose

The medication is a single-ingredient product intended for oral administration and is supplied primarily in the form of tablets. These pharmaceutical preparations include both immediate-release and extended-release formulations, which allow for controlled delivery of the active ingredient over varying periods. The general therapeutic role of Quetiapine is to facilitate mood stabilization and manage symptoms associated with psychosis. The drug acts as a dual antagonist on serotonin and dopamine systems. This mechanism helps regulate the signaling pathways that contribute to disorganized thinking and emotional volatility.

Regulatory References

  1. Quetiapine: MedlinePlus Drug Information
Advertisements

What side effects are possible with Quetiapine?

Possible side effects and safety information

Quetiapine's safety profile, documented in official regulatory sources such as the FDA and EMA, outlines the known adverse reactions and required safety monitoring. The effects are classified by frequency and associated System-Organ Classes ( SOCs), indicating its broad physiological impact.

Frequency-Classified Adverse Reactions

The following are examples of adverse effects categorized by their typical incidence based on regulatory data:

Classification Representative Effects
Very Common Somnolence, dry mouth, dizziness, weight gain, Extrapyramidal Symptoms ( EPS)
Common Constipation, Tachycardia, Orthostatic Hypotension, blurred vision, leukopenia

Serious Adverse Reactions and Key Safety Constraints

Official labeling highlights several serious and clinically significant risks, which include mandated warnings. These warnings cover the potential for Neuroleptic Malignant Syndrome ( NMS), Severe Neutropenia, and metabolic changes such as Hyperglycemia (including Ketoacidosis) and Dyslipidemia. There is also an established risk of Suicidal Thoughts and Behaviors, particularly in children and young adults.

Population- and Time-Related Safety Notes

Specific safety considerations exist for certain groups. Regulatory documents state that the drug is not approved for treating psychosis related to dementia in elderly patients, citing an increased risk of mortality and cerebrovascular events. Effects are also time-dependent: Orthostatic Hypotension is more common upon treatment initiation, while potential issues like Cataracts are associated with long-term exposure. Discontinuation may lead to withdrawal symptoms.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Suspected Quetiapine overdose requires immediate medical attention. Regulators mandate that individuals or caregivers contact the Poison Help line or emergency services immediately if excessive ingestion is suspected. The officially documented clinical manifestations often involve a severe exaggeration of the medicine's effects, primarily affecting the Central Nervous System (CNS) and the cardiovascular system.

Clinical Signs and Management

Presentations listed in regulatory labeling may include profound somnolence, excessive sedation, confusion, dizziness, tachycardia (rapid heart rate), and significant hypotension (low blood pressure). Overdose can progress to severe outcomes, including coma, respiratory depression requiring ventilation, and dangerous cardiac dysrhythmias due to QTc interval prolongation.

Official regulatory labeling confirms that no specific antidote is known for Quetiapine overdose. Therefore, management is strictly symptomatic and supportive, emphasizing continuous cardiovascular monitoring, including an electrocardiogram (ECG), and ensuring airway maintenance and adequate oxygenation. For severe hypotension, pressors such as noradrenaline may be used, but adrenaline is officially stated as needing to be avoided. The Extended-Release formulation requires extended monitoring due to its delayed onset and prolonged duration of symptoms. Furthermore, official data notes that elderly patients may be at an increased risk for severe toxicity.

Advertisements

Therapeutic Uses of Quetiapine

What Quetiapine Treats: Main Uses and Benefits

Quetiapine is commonly used to help manage symptoms associated with several serious mental health conditions, providing support that helps ease the overall symptom load. Primary applications include Schizophrenia, Bipolar Disorder (including acute manic, depressive, and mixed episodes), and use as an adjunctive treatment in Major Depressive Disorder (MDD).


Stabilization of Symptomatic Domains

This medication is applied in addressing symptom clusters that may become intense or disruptive, such as hallucinations, delusions, disorganized thinking, and extreme mood shifts. For patients experiencing these manifestations, it is relevant for easing the overall burden of distress. The use of Quetiapine is generally intended to support patients during acute symptomatic periods and assist with long-term functional stability.


Quick Fact: Support for Psychotic Symptoms

Quetiapine is considered relevant for managing the positive symptoms of psychosis, such as delusions and hallucinations, which are symptoms related to systemic imbalance and may create noticeable functional strain.

Regulatory References

  1. NIH MedlinePlus Drug Information overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Quetiapine — Official Regulatory Information


Eligibility Scope

  • Populations for whom use is allowed (as stated in label): Adults (18+); Adolescents (13–17) for Schizophrenia; Children/Adolescents (10–17) for Bipolar Mania.
  • Populations for whom use is not recommended (if applicable): Children and adolescents below 18 years of age (due to lack of long-term data in some regions); use in pregnancy and lactation.
  • Populations for whom use is contraindicated: Patients with known hypersensitivity to the drug; Elderly patients with dementia-related psychosis (due to increased risk of death, as per FDA Boxed Warning); concomitant use with strong CYP3A4 inhibitors (per some regulatory bodies).

Age-related and Condition-specific Eligibility Rules

  • Age-related eligibility rules: The minimum approved age is 10 or 13, depending on the indication; use in children under 10 is not approved. Slower titration is advised for the elderly due to reduced clearance.
  • Condition-specific eligibility rules: Patients with hepatic impairment require conditional use with a slower titration rate. Individuals with a low white blood cell count or cardiovascular disease require caution and special monitoring.
  • Pregnancy and lactation eligibility status: Use during pregnancy is permitted only if the potential benefit justifies the potential risk. Breastfeeding is not recommended.

Resulting Eligibility Structure

Regulatory documents define eligibility by absolute contraindications (e.g., elderly patients with dementia-related psychosis) and age-specific approval that limits use in pediatric groups. Eligibility for patients with conditions like hepatic impairment or cardiovascular disease is conditional, requiring mandatory caution or slower titration as specified in official labeling.

Advertisements

What should I know about interactions with other medicines?

Quetiapine’s official interaction profile is governed primarily by its metabolism via the cytochrome P450 CYP3A4 enzyme, which defines the clinically significant pharmacokinetic interactions.

Pharmacokinetic and Exposure Modification

Co-administration with strong CYP3A4 inhibitors, such as ketoconazole or ritonavir, is a pharmacokinetic interaction that decreases the clearance of quetiapine, resulting in increased systemic plasma concentrations (exposure). Conversely, potent CYP3A4 inducers, including phenytoin, rifampin, and the herbal product St. John’s wort, increase the drug’s clearance, leading to decreased plasma concentrations and potential loss of intended effect. These exposure-modifying interactions necessitate specific regulatory constraints.

Pharmacodynamic and Substance Restrictions

Pharmacodynamic interactions are officially documented as additive effects. Co-administration with other centrally acting drugs may enhance sedation, while use with antihypertensive agents may lead to an additive hypotensive effect. Administration constraints related to food and substance restrictions are also noted in regulatory labeling. The extended-release (XR) formulation requires administration without food or with a light meal to prevent a substantial, official increase in systemic exposure. Consumption of grapefruit or grapefruit juice must be avoided due to its inhibitory action on CYP3A4. A final consideration is noted for patients with hepatic impairment, who show increased susceptibility to exposure-related effects due to their underlying metabolic profile.

Advertisements

Mechanism of Action

How Quetiapine Works at the Biological Level

Quetiapine, an atypical antipsychotic, exerts its effects through a complex multireceptor antagonist profile, acting on key neurotransmitter systems in the central nervous system. Its primary mechanism involves modulating pathways associated with dysregulated physiological responses, resulting in altered neuronal signaling patterns.

Receptor Targets and Binding Kinetics

The drug acts as an antagonist at both the serotonin 5-HT2A and dopamine D2 receptors. Exhibiting differential affinity for the 5-HT2A receptor relative to the D2 receptor, it modulates the activity of systems where these specific transmitters dominate. A key characteristic is its transient D2 receptor occupancy, which contributes to a kinetic profile characterized by rapid association and dissociation.

Pathway Modulation by Active Metabolite

The active metabolite, norquetiapine (N-desalkylquetiapine), is critical to the drug's overall mechanism. It functions as an inhibitor of the norepinephrine transporter (NET) and a partial agonist at the 5-HT1A receptor. This dual action increases synaptic concentrations of norepinephrine and serotonin, modulating the activity of monoamine-dependent neural circuits.

Secondary Receptor Activity

Quetiapine also demonstrates antagonism at histamine H1 receptors and adrenergic alpha1 receptors. The H1-blocking effect mediates changes in central nervous system activity, while alpha1 receptor blockade modulates vascular regulation and associated downstream physiological consequences.

Advertisements

Dosage and Administration Information

How to use Quetiapine: Administration Guidelines

Quetiapine is administered to support proper absorption and consistent therapeutic levels. The following parameters describe the standard methodology for its use.


Administration Scope

Feature Guideline
Route of Administration Oral (PO). Available as Immediate-Release (IR) and Extended-Release (XR) tablets.
Dosing Schedule Requires a structured initial dose titration (gradual increase over several days) to establish the therapeutic maintenance dose.
Timing in Relation to Meals Extended-Release (XR) tablets are generally taken without food or with a light meal (e.g., approximately 300 calories). Immediate-Release (IR) can be taken with or without food.
Special Conditions XR tablets must be swallowed whole and must not be split, chewed, or crushed.

Frequency and Adjustments

  • Frequency: The IR tablet is typically administered two or three times daily, while the XR tablet is administered once daily, often in the evening.
  • Age and Impairment: Elderly patients and individuals with hepatic impairment require a lower initial starting dose (e.g., 25 mg or 50 mg per day) and a slower titration rate. Specific titration schedules also exist for adolescents.
  • Missed Dose: If a dose is missed, it is taken as soon as remembered, unless it is nearly time for the next scheduled dose. A double dose is not taken to compensate for a missed one.

Connection to the Overall Use Protocol

The administration protocol involves a precise methodology for Quetiapine use. This includes adherence to the initial low-dose titration schedule and follows specific rules for formulation administration, such as the requirement to swallow the XR tablet whole. This structure is designed to ensure the medicine is absorbed and administered consistently.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Quetiapine

Evidence for use in Schizophrenia

The available evidence structure for this compound in schizophrenia is primarily rooted in short-term Randomized Controlled Trials (RCTs) that typically spanned about six weeks. These studies were used in research exploring how symptoms change over time and examining symptom intensity or variability. Research examined changes in the measures used to track the phases of heightened symptom activity and outcomes reflecting overall daily functioning. Subsequent open-label trials have explored how the compound was observed in patient populations over a longer maintenance period.

Findings describe patterns observed in the studies related to differences in certain measured symptom scores compared to those who received an inactive substance (placebo). The evidence contributes to understanding symptom patterns over the initial weeks, but the results apply only to the populations studied. Data for adolescents are available from short-term trials, but long-term effects are not fully established for this younger population.


Evidence for use in Bipolar Disorder (Manic and Depressive Episodes)

Research has evaluated the compound in conditions characterized by fluctuating or episodic manifestations, specifically the acute manic and depressive episodes of Bipolar I and Bipolar II disorder. Researchers conducted trials to assess short-term symptom patterns, monitoring outcomes capturing phases of heightened symptom activity. Research examined the compound as a single administered substance (monotherapy) and as an additional agent alongside other established medications (adjunctive treatment).

Research highlights the measured changes in mood rating scale scores across the study period for both the acute phase of mania and the acute phase of depression. For long-term use, studies monitored patients to examine temporary physiological imbalance and found data show patterns related to changes in stability measures compared to an inactive substance. However, findings were mixed across studies, and the duration of follow-up for maintenance remains limited.


What is Still Uncertain about Quetiapine

This section synthesizes the main evidence gaps across all indications. The research provides context but not individual predictions. Long-term effects are not fully established across all approved uses, particularly regarding extended safety outcomes and the stability of any observed patterns beyond 1–2 years. Furthermore, data for certain groups remain insufficient, including a lack of studies in lower-risk patients or those with specific, rare comorbidities. Finally, research focusing on the compound at very low doses is not well-documented by formal clinical trials, reminding us that research describes group patterns, not personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Quetiapine (FAQ)

Q: Is Quetiapine a sleeping pill or an anti-psychotic?

Official information classifies Quetiapine as an atypical antipsychotic medication. It is approved to treat conditions such as schizophrenia and bipolar disorder. However, a part of its mechanism of action involves blocking certain histamine receptors, and this receptor activity may be associated with effects such as sedation.


Q: Can Quetiapine make you feel tired or drowsy during the day?

Yes, regulatory documents list somnolence, which is the medical term for drowsiness or excessive tiredness, as a very common side effect. Official warnings note that Quetiapine has the potential to cause cognitive and motor impairment, which is a factor to consider regarding daily activities.


Q: How long does it take for Quetiapine to start working for mood swings?

Clinical trials used to study Quetiapine’s effectiveness for the acute manic or depressive episodes of bipolar disorder were typically short-term. These studies ranged from approximately 3 to 12 weeks in duration. This provides context on the typical timeframe researchers use to evaluate changes in symptoms.


Q: Is it normal to have vivid dreams or nightmares on Quetiapine?

While vivid dreams are not typically listed as a common adverse reaction in the main clinical trial data, official labeling confirms that nightmares have been reported during the post-marketing experience of the drug. This information is based on reports received after the medication was made available to the public.


Q: Can you drink alcohol while taking Quetiapine?

Regulatory guidelines recommend against the concurrent use of alcohol while taking Quetiapine. This is because the medication can enhance the cognitive and motor effects of alcohol, and combining them can lead to increased sedation and significantly greater impairment.


Q: Is it true that Quetiapine can cause elevated cholesterol levels?

Yes. According to official warnings, treatment with Quetiapine has been associated with dyslipidemia, which refers to abnormal levels of fats, including cholesterol, in the blood. This risk indicates that monitoring of blood lipid levels may be required during treatment.


Q: What are the long-term side effects associated with Quetiapine use?

The official product information highlights that long-term use is associated with a risk of certain side effects. These risks include the potential for Tardive Dyskinesia, which involves involuntary movements, and the development of Cataracts. These potential issues may require regular monitoring by a healthcare provider.


Q: What should I expect when trying to stop taking Quetiapine?

If Quetiapine is stopped abruptly, regulatory information states that withdrawal symptoms may occur. These symptoms can include insomnia, headache, nausea, vomiting, dizziness, and irritability. Official guidance emphasizes that discontinuation should be managed gradually to help reduce these effects.


Q: Does Quetiapine affect heart rhythm or cause palpitations?

Yes, official safety data indicates a potential impact on the heart. Tachycardia (fast heartbeat) is listed as a common side effect. The drug also carries a warning about the potential for QT prolongation, which refers to a potential abnormality in the heart’s electrical activity.


Q: Can Quetiapine be used to treat anxiety disorders?

No. Based on the official prescribing information, Quetiapine is not approved by the FDA for the treatment of primary anxiety disorders. Its approved uses are centered on conditions like schizophrenia and bipolar disorder.


Q: When should I take Quetiapine—morning or night?

For the Extended-Release (XR) formulation, regulatory instructions state that it should generally be administered once daily, preferably in the evening. The timing is specified in the regulatory guidelines for proper administration.


Q: Can Quetiapine affect my ability to drive or operate machinery?

Yes. The medication carries an official warning regarding the potential for cognitive and motor impairment. Patients should use caution regarding driving or operating complex machinery until the effects of the drug are known.


Q: Does Quetiapine cause dry mouth, and what helps with that?

Yes, dry mouth is listed in regulatory documents as a very common adverse reaction. Official prescribing information details this side effect but does not provide recommendations for specific management or remedies.


Q: Does Quetiapine affect libido or sexual function?

Official safety documents indicate that the drug can cause hyperprolactinemia, an increase in the hormone prolactin. Elevated prolactin levels may be associated with changes in sexual function or libido.


Q: Can Quetiapine cause restless legs syndrome?

Yes, official regulatory documents from certain international bodies list restless legs syndrome (RLS) as an adverse reaction that has been reported during treatment with Quetiapine.


Q: Does Quetiapine interact with high blood pressure medications?

Yes. Official information notes that Quetiapine can cause hypotension (low blood pressure). Because of this, taking it with other antihypertensive agents (high blood pressure medications) may result in an additive hypotensive effect, meaning the drop in blood pressure could be greater.


Q: Is Quetiapine habit-forming or addictive?

Quetiapine is not classified as a controlled substance by the U.S. government. However, regulatory documents acknowledge that cases of misuse and abuse have been reported, and these reports have primarily involved individuals with a history of substance abuse.


Q: What effect does Quetiapine have on concentration or memory?

The official product label contains a warning about the potential for the medication to cause cognitive and motor impairment. This means that concentration, memory, and physical coordination may be affected.


Q: Does Quetiapine cause blurry vision?

Yes. Blurred vision is listed in the official safety information as a common adverse reaction associated with the use of Quetiapine.


Q: What is the maximum amount of time someone can safely take Quetiapine?

Quetiapine is officially approved for the maintenance treatment of conditions like schizophrenia and bipolar disorder, implying long-term use is expected. However, regulatory documents indicate that the long-term safety profile and effects are still being studied.


Q: Is it normal for Quetiapine to increase hunger?

Yes. Increased appetite is listed in regulatory documents as a common adverse reaction. This increased hunger is one of the factors that can contribute to the potential for weight gain associated with the medication.


Q: Is there a link between Quetiapine and vision problems like cataracts?

Yes. The official prescribing information indicates that lens changes, including the development of cataracts, have been observed in some patients during long-term Quetiapine treatment. Due to this potential issue, regular eye examinations may be required for monitoring.


Advertisements

How should Quetiapine be stored and disposed of?

Official Storage Requirements

Quetiapine tablets must be stored at controlled room temperature, typically between 20 C and 25 C, and kept away from heat, moisture, and direct light. It is essential to keep the medication in a closed container and keep from freezing to maintain stability. The tablets must not be used after the expiration date printed on the packaging.

Child Safety and Disposal

Regulatory requirements universally mandate that Quetiapine must be kept out of the sight and reach of children at all times. For disposal of expired or unused medicine, the official guidance prioritizes secure disposal methods such as drug take-back programs or mail-back options. The medication must not be thrown away in household waste or disposed of via wastewater systems to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quetiapine found in:

A-Z Index: